Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDM2005 + lenalidomide
- Development stage
- Unknown
- Lead developer
- Huadong Medicine
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
HDM2005 + lenalidomide is an investigational combination regimen being evaluated for the treatment of B-cell malignancies, particularly relapsed or refractory mantle cell lymphoma (MCL). HDM2005 is a Class 1 innovative antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). It is composed of a humanized IgG1 monoclonal antibody conjugated to the microtubule-disrupting cytotoxic payload monomethyl auristatin E (MMAE) via a proteolytically cleavable linker. Lenalidomide is an oral immunomodulatory drug (IMiD) that binds to the cereblon (CRBN) E3 ubiquitin ligase complex, leading to the degradation of transcription factors such as Ikaros (IKZF1) and Aiolos (IKZF3), which results in anti-proliferative and pro-apoptotic effects. The combination, often administered with rituximab, aims to provide synergistic anti-tumor activity by combining targeted cytotoxicity with immunomodulation.
- Other names
- HDM2005 plus lenalidomideHDM-2005 plus lenalidomideHDM 2005 plus lenalidomide
02
Targets
ROR1 (Receptor tyrosine kinase-like orphan receptor 1)TUBB (Tubulin (alpha and beta subunits))CRBN (Cereblon)
Beyond the preview
Go deeper on HDM2005 + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDM2005 + lenalidomide.